Ganstigmine. Chiesi.
Ganstigmine (CHF-2819) is being developed by Chiesi as a potential treatment for neurodegenerative and cognitive disorders. The drug was in phase IIa studies in the US for senile dementia associated with Alzheimer's disease (AD) by mid-2000, and phase IIb trials in AD patients were scheduled for early 2001, with these ongoing in 2002.
Johnson
Anthony
A
Anthony Johnson Consulting, Durham Close, Sawbridgeworth, Hertfordshire, CM21 0HD, UK. johnson@ntlworld.com
D000470:Alkaloids / Q000737:chemistry / Q000627:therapeutic use*; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D000818:Animals; D002219:Carbamates / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D013678:Technology, Pharmaceutical / Q000379:methods
D000470:Alkaloids; D002219:Carbamates; D015507:Drugs, Investigational; C447079:ganstigmine